Life Sciences Archive » November, 2022

Life Sciences - November, 2022

283 articles

• CDC Broke Gilead HIV Research Deal, Claims Court Rules
• Riding Circuit: December's Notable Appellate Arguments
• Immig. Board Told To Consider Mom's Missed Hearing Excuse
• Femtech Cos. Should Prioritize Pursuing IP, Attys Say
• 7th Circ. OKs Indiana Fetal Remains Requirement
• J&J Says Amgen Biosimilar Infringes Patents For $9B Product
• Medical Pot User Claims Labcorp Wrongly Denied Him A Job
• FTC Told DOD Designation Helps Illumina-Grail Deal Appeal
• Roche Escapes Ex-Service Member's Anti-Malarial Drug Suit
• Gov't Contracts Of The Month: Blue Origin, SpaceX, Internet
• HHS Plans ADR Overhaul For Drug Discount Rows
• The Fed. Circ. In November: The Presumption Of TM Validity
• Corteva Buys Latham-Guided Plant Science Co. In $1.2B Deal
• NJ Judge Sends 33 J&J Implant Suits Back To State Court
• NY Nursing Home's Neglect Tied To Patient Deaths, State Says
• Biopharm Co. Stockholders Challenge Director Pay In Del. Suit
• Abbott Sued Over Formula Linked To Premature Baby Death
• Johns Hopkins Breached Keytruda Deal, Merck Sharp Says
• Drugmaker Astellas Has Claims For DOJ Settlement Coverage
• Roundup Buyers Seek OK Of $45M False Ad Settlement
• Time For USPTO To End Marijuana Company TM Disclaimers
• EU Reaches €157M Settlement Over Chemical Cartel
• Gordon & Rees Hires Faegre Drinker Product Liability Duo
• Shire Wants 11th Circ. To Review Kidney Failure Lawsuit
• Honeywell Hit With $10M Suit Over 'Deformed' N95 Masks
• Boston Scientific Acquires Medical Tech Co. In $615M Deal
• Tribal Corp, Stanford Sort Out Contract Fight Over Drug IP
• Juno Urges Justices To Hold Patent Case Until Amgen Ruling
• Lack Of Facts Dooms Class Cert Over Takeda Gout Drug
• Monster Leads Push For Litigation Committee In Vital's Ch. 11
• N95 Seller's Attys Sanctioned Over Missed 3M Deadlines
• Procter & Gamble Throat Drops Have No Lemon, Suit Says
• Fed. Circ. Urged To Revive Lymphoma Drug Patent Case
• 3M On Hook For One Deductible For Warming Device Defense
• Catching Up With Delaware's Chancery Court
• Coppertone Parent Hit With Fraud Suit Over Sunscreen Labels
• BigLaw Firms Help Create Term Sheet Template For Startups
• Law Schools Are Right To Steer Clear Of US News Rankings
• How Firms Are Getting The Most Out Of Their Pro Bono Work
• The 2022 Law360 Pulse Social Impact Leaders
• Feds Seek Prison For Exec's FDA Fraud After 1st Circ. Flip
• UK Litigation Roundup: Here's What You Missed In London
• FDA Asks Companies For Cigarette Packaging Plans
• 5 Years In, Opioid Attys Talk Historic Saga's Progress & Future
• Ex-Indivior Exec Says 5-Year Federal Program Ban Isn't Fair
• Holmes Should Serve 11-Year Sentence In Texas, Judge Says
• High Court Told Plenty Of Circuit Judges Disagree On FCA
• NC Sues 3M, DuPont Over 'Forever Chemical' Contamination
• DEA Legalizes Cocaine Derivative, Rejects Pot Comparisons
• Del. Jury Says AngioDynamics Infringes CR Bard Patents
• Pharma Co. Asks For Stay To Appeal 'Orange Book' Delisting
• Why BIPA Litigation Could Be A Death Knell To Cannabis Cos.
• Honigman Announces Corporate Partner In Chicago
• Litigation Funders Seek Transparency In Disclosure Debate
• 7 Key Takeaways For Litigating Willful Patent Infringement
• 4 Firms, 2 Years, 1 Suit And, Finally, A Done UnitedHealth Deal
• Ga. Supreme Court Revives 6-Week Abortion Ban
• J&J Unit Invalidates Spinal Implant Patent On Eve Of Trial
• Court Told Gov't Admitted To License Agreement In Nixed Suit
• Claims Court Finds CDC Broke Gilead Deal Over HIV Research
• Tribes Urge Judge To Find Ore. Irrigation Plan Violated ESA
• Bayer Alka-Seltzer Falsely Hypes Honey And Lemon, Suit Says
• Meridian Bioscience's $1.53B Sale Clears Antitrust Hurdles
• Abbott Tries Again To Sink HIV Test Patent
• FDA Targets 5 CBD Cos. Hawking Food And Beverages
• Cos. Should Start Thinking About IP Protection For Quantum
• PREP Immunity Applies To Swab Patent Suit, Fed. Circ. Told
• Anticipating The New Congress' Private Sector Investigations
• Ex-Rutgers Prof Accused Of Defamation Over Job Reference
• 5 Principles For Better Professional Development Programs
• Teva, Allergan Finalize Multibillion-Dollar Global Opioid Deals
• PTAB Told Chemical Co.'s Tech Has 'Full Promise' Of CRISPR
• Holmes Faces Uphill Battle Fighting 11-Year Prison Term
• Univar Slapped With ERISA Suit Over Unpaid Contributions
• UnitedHealth Closes Merger But DOJ Keeps Fighting
• WIPO Says China Is Filing The Most Patent, TM Applications
• My Favorite Law Prof: How I Learned To Practice With Passion
• Ga. Court Is Asked To Enforce Abortion Law During Appeal
• Merck To Buy Bone Marrow Cancer Firm In $1.35B Deal
• Attys Secure $91.7M In Monsanto PCB Suit
• Catching Up With Delaware's Chancery Court
• Clinical Trial Co. CEO Can't Avoid Fraud Charges Over Delay
• Hyman Phelps Brings On DOJ Consumer Protection Vet In DC
• DOJ Will Ask DC Circ. To Block UnitedHealth-Change Deal
• Del. Court Says Pharma Co. Must Delist 'Orange Book' Patent
• Biden Expected To Sign Pot Research Bill Into Law
• Sterigenics Prevails In Second Ethylene Oxide Trial
• Last Call For 2022 As IPO Prospects Line Up To Go Public
• FDA Faces Texas Suit Over Approval Of Abortion Drugs
• 1st Circ. Tosses Aegerion Rep's Drug Fraud Convictions
• Congress Should Pass Tillis-Coons Patent Eligibility Bill
• FTX Chaos, Texas Utility Reorg OK'd, Student Debt Relieved
• Fla. Commissioner Appeals Ruling Denying Pot Patients Guns
• Elizabeth Holmes Gets Over 11 Years For Theranos Fraud
• Exculpation Clause Ruling May Dissuade Some Ch. 11 Filings
• Sen. Lee Floats Bill To Drop Biosimilar Hurdle
• State AG Consumer Protection Shift Isn't An Election Fad
• All-Women White Collar Boutique Adds Ex-Boston Prosecutor
• Baxter Agrees To Drop Fraud, Patent Case Against B. Braun
• UK Litigation Roundup: Here's What You Missed In London
• Woman Hasn't Linked Emissions To Cancer, Sterigenics Says
• Holmes Likely To Get Prison With Pause For Appeal, Attys Say
• IP Forecast: Winery, Its Former Lawyer To Face Off In TM Row
• Akin Gump Gets Green Light To Represent Endo Claimants
• Allergan Drops Part Of IBS Drug Patent Suit Against MSN
• New Orleans Litigation Outfit Adds New Name Partner
• Sens. Pitch Bill To Streamline Research Into Schedule I Drugs
• Ill. City Says Express Scripts Spoiled Docs In Acthar Case
• NJ Pharma CEO Indicted In $4M Embezzlement Scheme
• Moderna Ruling Misses On 'Products Sold To US Government'
• Whistleblower Tells Justices FCA Dismissal Authority Limited
• Indivior Spars With States, Suboxone Buyers Over Trial Date
• Deals Rumor Mill: Binance, SBF, Forbes Media
• Bipartisan Marijuana Research Bill Headed To Biden's Desk
• J&J Tells Justices $302M Mesh Fine Part Of 'Dangerous' Trend
• Patient Wants Special Master DQ'd In J&J Hip Implant MDL
• Masimo Prevails As Judge Rules Ex-Exec Took Trade Secrets
• 8th Circ. Backs CVS Win In TCPA Suit Over Fax
• Elizabeth Holmes Slams Feds' Bid For 15 Years Behind Bars
• FDA Cracks Down On Vapes That Look Like Toys, Food
• What New Data On FCA Enforcement Tells Us
• In Pfizer Win, PTAB Says Rival's Gene Therapy Wasn't New
• N95 Seller Must Give 3M Discovery Or Face Sanctions
• How Mayo V. Prometheus Strays From Patent Precedent
• NYC Pharmacy Owners Plead Guilty To COVID Medicare Fraud
• Ky. Gov.'s Executive Order Allows Out-of-State Medical Pot
• Questions To Ask Before Making A Lateral Move As Partner
• Lawmakers Urge House Committee To Act On Pot Reform
• Veterinarian, Horse Trainer Get Prison Time In Doping Case
• CVS Drug Buyers Face Skeptical 9th Circ. In $121M Retrial Bid
• Fed. Circ. Allows AbbVie, J&J To Fend Off Imbruvica Generic
• Seagen Looks To Nix Daiichi Win In Cancer Drug Dispute
• E-Cig Company's Appeal Premature, FDA Tells DC Circ.
• Ill. City Can't Escape Overflowing Sewage Suit, Judge Says
• Corps Must Protect Okefenokee From Mine, Green Groups Say
• FCA Takeaways From Courts' Recent Approach To Escobar
• Chamber Urges Full 11th Circ. Review Of Ga. Roundup Case
• White House Wants $48B More For COVID, Ukraine Battles
• Natera Says Fed. Circ. Panel Rightly Axed DNA Test Patents
• McCarter & English Must Produce Docs In Biotech's Suit
• HHS, Drug Cos. Spar Over Pharmacy Limits In Discount Law
• Cooley-Led Oncology Firm Prices $94M IPO Below Range
• Ga.'s 6-Week Abortion Law Is Unconstitutional, Judge Rules
• 11th Circ. Doubts Link Of Deposition Texting To Arbitral Award
• Why PTAB 'Step 2B' Reversal Rates Are Falling
• Takeda To Pay $22M To End Challenge To 401(k) Lineup
• Walmart Confirms $3B Deal Over Pharmacies' Opioid Sales
• Drug Lobby Touts Pfizer's Kickback Challenge At High Court
• 6th Circ. Allows Opioid Judge's 'Unusual' Bellwether Approach
• Allergan, Merz's $54.4M Nameda Pay-For-Delay Deal Wins OK
• FTC Says "Orange Book" Abuse Blocks Drug Competition
• Sun Can't Say Allergan Used Secret Info To Grow Patent Suit
• Colorado Ballot Measure Decriminalizing Psychedelics Passes
• Catching Up With Delaware's Chancery Court
• NJ Man Cops To Insider Trading In Atty Info-Poaching Case
• My Favorite Law Prof: How I Learned To Argue Open-Mindedly
• Pot Researcher's Suit Over DEA Delays Gets Tossed
• Covington-Led Indivior To Buy US Drug Co. Opiant For $145M
• Holmes Seeks Home Confinement As Feds Urge 15 Yrs. Prison
• UK Litigation Roundup: Here's What You Missed In London
• 6th Circ. Won't Uproot Seed Biz's $7M Trade Secret Win
• Justices Seem Less Receptive To SG's Take On IP Cases
• Illumina Defends Grail Deal To FTC Commissioners After Win
• McKinsey Wants NY Opioid Suits Moved To Bankruptcy Court
• Feds Charge Ex-Mylan CIO With Insider Trading Scheme
• HHS Office To Avoid Anti-Abortion States For Pregnant Minors
• Medical Device Co. D R Burton Cleared In NC Patent Trial
• Viatris Sways Judge To Ax AstraZeneca Inhaler Patent
• Health Hires: Epstein Becker, Cassava Sciences
• Former Exec, Partners Of Vape Co. Drop Wrongful Firing Suit
• Pot Pill Co. Ordered To Pay $5M In SEC Fraud Suit
• ABA's No-Contact Rule Advice Raises Questions For Lawyers
• Big Pharma Opens New Front In War On Kickback Restrictions
• Amyris Investors Reach $13.5M Deal In Inflated Royalties Suit
• Flint Residents Shouldn't Depose Former EPA Head, DOJ Says
• Natural History Museum Fights To Pause COVID Coverage Suit
• FTC Mulls Proper Standard On Staffers' Juul-Altria Appeal
• Walgreens Faces $10B Opioid Trial Threat Despite $5B Deal
• Drug Atty Ads Risk 'Serious Harm,' W.Va. AG Tells High Court
• Teva Wins $176M From Eli Lilly In Migraine Drug Patent Trial
• Drug Buyers, States Want To Depose Indicted Ex-Taro Exec
• SoClean Wins TM Preliminary Injunction Fight At Fed. Circ.
• Firm Touts Diversity In Bid To Lead COVID Drug Claims Suit
• 4 Key Skills For An Effective Attorney Coaching Conversation
• Ga. City Worker Claims Race Bias During Pandemic
• Veteran Pharma Atty Joins Xenon As Chief Legal Officer
• NM Cannabis Co. Wants Insurance Suit Back In State Court
• Maryland And Missouri Legalize Pot, 3 Others Just Say No
• Control Of Congress Too Close To Call
• California, Vermont, Michigan Voters Back Abortion Rights
• Arkansas Voters Say No To Cannabis Legalization, Taxation
• 'Busy' Abbott Exec Has Time To Get Deposed, Judge Says
• Biopharma Co. Hit With Investor Action Over COVID Treatment
• 6th Circ. Says Depos Don't Force Trial Testimony In Flint Case
• Fox Rothschild Hires Loeb & Loeb IP Partner For NY Office
• Apotex Dodges Horizon Patent Suit Over Generic Pennsaid
• FCA Whistleblower Trying To 'Gin Up A Split,' High Court Told
• Ex-Theranos CEO Elizabeth Holmes Loses Bids For New Trial
• How Civilian Attorneys Can Help Veterans
• Attys Seek $1.65M Award For Altor-NantCell Deal In Del.
• From Courts To Polls: BigLaw Turns Out To Protect The Vote
• NY Judge Signs Off On J&J Counterfeit Meds Injunction
• Eli Lilly Flips Teva 'Free Ride' Claim As Migraine Trial Wraps
• Canadian Cancer Co. Accused Of Failing To Pay NC Exec
• Musk's $56B Tesla Pay Trial May Spur More Exec Comp Fights
• FDA Warns Court Not To Side With Sandoz In Drug Challenge
• 11th Circ. Backs Dismissal Of Zantac MDL 'Shotgun Pleadings'
• Cravath-Led Viatris Unveils Ophthalmology Buys Worth $750M
• W.Va. Urges 4th Circ. To Reverse Trans Medicaid Bias Ruling
• Walmart Rips 'Monday-Morning Quarterbacking' In Opioid Suit
• Delaware Gets $2.7M Atty Fee Request OK'd In Opioid Deal
• DuPont Spinoffs Must Face PFAS Claims, NC Justices Say
• Sterilization Plant Opposes New Suit For Workers
• Jury Clears Scrubs Startup Figs In Rival's False Ad Suit
• 11th Circ. Revives PGA Coach's Kidney Disease Suit
• Monsanto Asks Full 11th Circ. To Review Roundup Ruling
• Biogen Agrees To 12,000-Person Class In 401(k) Suit
• Catching Up With Delaware's Chancery Court
• Ex-Theranos Exec Balwani's Sentencing Delayed To December
• My Favorite Law Prof: How I Learned That Culture Shapes Law
• UT Austin Restaurant Loses COVID-19 Coverage Suit
• Alcon Gets PTAB Win In Eye Surgery IP Fight With J&J Unit
• 5 States Vote On Legalizing Pot, And 1 Votes On Psychedelics
• Justices Reject Case Over Patent 'Possession' Requirement
• HIV Drug Buyers Win Cert. In Gilead, Janssen Antitrust Suit
• SF-Walgreens Opioid Trial Called Off Amid Settlement Talks
• Opana Buyers' $145M Deal With $50M In Atty Fees Gets Final OK
• Feds Escape Suit Over Delayed Narcolepsy Drug
• FOIA Suit Over DNA Testing At Border Largely Resolved
• FDA, USPTO Set January Date For Public Input On Competition
• Key Bankruptcy Reforms In Reach, Whoever Wins Congress
• Settlement Comes Mid-Trial In Ga. Health FCA Case
• Pharma Cos. Keep Win In Off-Label Heart Drug Suits
• Texas Court Again Revives Suit Over Stryker Rep Assault
• McKesson OKs $141M Investor Deal Over Generic Price-Fixing
• Full 9th Circ. Passes On Atty's FCA Loss Against Allergan
• Fed. Circ. Doubts Vaccine Delivery IP Wrongly Axed By PTAB
• CBD Co. Says Judge's Memorandum On Counterclaims Wrong
• 5 Firms Lead Giant Biogene's Downsized $70M HK IPO
• Endo Claimants' Request To Hire Akin Gump Draws Objection
• FDA And FTC Warn CBD Shop Not To Sell False COVID Cures
• McCarter & English Aims To Shield Docs In Malpractice Suit
• What To Expect From The Post-Midterms Lame-Duck Session
• UK Litigation Roundup: Here's What You Missed In London
• Supreme Court Will Tackle Patent Enablement In Amgen Case
• CBD Co., Founder Ordered To Arbitrate Over $5M Tax Bill
• Walgreens Lied About Medicaid Compliance, 4th Circ. Told
• 5 Times That Stood Out In NY's Roller Coaster Opioid Case
• IP Forecast: VLSI Patent Battle Against Intel Goes For Round 4
• Calif. Court Delays SmileDirect's Competition Case
• 9 Legal Ethics Considerations In Natural Disaster Preparation
• 3rd Circ. Preview: Nov. Sees Uber Arbitration, Drug Discounts
• PTC Therapeutics Shareholder Sues In Del. Over Director Pay
• Study Claims Diagnostics Innovation Isn't Tied To Investments
• A Divided Congress May Increase Companies' Political Risks
• State Farm Tells 5th Circ. No Virus Coverage For Orthopedists
• NY Reaches $523M Opioid Deal With Teva
• After Pharmacy Deals, New Opioid Sellers In Legal 'Bull's-Eye'
• Moderna Loses Bid To Punt COVID Vax Patent Suit To Gov't
• Cherokee Nation Settles Ex-Bellwether Opioid Suit Vs. CVS
• 9th Circ.'s Weariness Of TCPA Award May Quell Big Paydays
• Union Says Long Island Hospital Owes Benefits Funds $1.7M
• Gov't Lodges Rival Early Win Bid In Gilead HIV Patent Row
• Calif. County Can Sue State Prison System Over Pollution
• 'Brilliant' GW Law Patent Scholar Dmitry Karshtedt Dies At 45
• Pollution Exclusion Frees Insurer From $175M Suit
• Sotera Health Hires Longtime GE Attorney As General Counsel
• Rwanda Alleges $40M Cancer Drug Investment Fraud
• PTAB Upholds IP Involved In $272M Genetic Testing Verdict
• Gilbert LLP Aims To Ensure It Gets Paid For Del. Opioid Work
• Rogers Explores Alternatives After DuPont Terminates Merger
• USPTO Administrative Patent Judge Joins Oblon McClelland
• CVS, Walgreens Offer $10B To End Nationwide Opioid Suits
• A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
• 'Most Dangerous' Roundup Made Landscaper Sick, Jury Hears
• Feds Want Whistleblower's $1.4B Tamiflu FCA Suit Tossed
• Tribe Sues Golf Cart Co. Over Pandemic Malfunction Losses
• Fed. Circ. Iffy On Alvogen's Bid To Unblock Generic Opioid
• ITC Judge Clears COVID Swab Makers Of Infringing Patents
• Baker Botts Snags New M&A Co-Lead From Holland & Knight
• Cannabis Cos. Must Brace For Emerging Product Risks
• Ethicon, J&J Beat Back Attempt At New Pelvic Mesh Trial
• Cravath, Sullivan & Cromwell Drive J&J's $16.6B Abiomed Buy